Get started
Work

P554: Cost not a barrier for adopters of pharmacogenetic testing: Results from a study of causal models in different healthcare systems

Year: 2024
Type: article
Study design: Observational Study
Abstract: Pharmacogenetic testing has demonstrated benefits, such as reducing the time to effectiveness of medications. However, use of pharmacogenetics has spread slowly in routine care. Variable beliefs about advantages of testing and policies for coverage have hindered widespread uptake. Less is known about what facilitates adoption. To identify potential areas for intervention, we conducted a study to understand what factors differentiated adopters vs non-adopters of pharmacogenetic testing for CYP2D6 or CYP2C19 among prescribers of antidepressants using a novel mixed-methods approach.
DOI: 10.1016/j.gimo.2024.101453
Authors: Nina Sperber, Megan Roberts, Lisa Bendz, Sarah Gonzales, Susanne Haga, Natasha Petry, Laura Ramsey, Ryley Uber, Ryanne Wu, Deborah Cragun
Institutions: Durham VA Health Care System, Duke University, Duke University Health System, Children's Mercy Hospital, Geisinger Health System, University of South Florida
Language: English
Subfield: Pharmacology
Open Access status: gold
Estimated APC paid: $3,200
OpenAlex ID: W4392606853
FWCI:
Cites:
Cited by:
Related to: 10